The FDA’s Final Rule on LDTs and What It Means for Independent Medical Labs (Updated)

Article Update: This article (updated from its original April 2, 2025, publication) revisits the fate of the LDT final rule and what's next for clinical labs and pathology groups.

LDT Regulation in 2025: The FDA Final Rule That Was Stopped, and What Comes Next for Clinical Laboratories

In 2025, the FDA's attempt to implement a final rule regulating Laboratory Developed Tests (LDTs) as medical devices was halted by a federal court ruling in March, which found the agency overstepped its authority; the FDA then officially rescinded its rule in September 2025, reverting to the previous regulatory approach, leaving LDTs primarily under CMS oversight via CLIA, which was a significant win for medical laboratories and patients.

What follows is an outline of the current regulatory landscape (with a focused look at what remains unresolved and uncertain for clinical laboratories and pathology practices), along with a deep dive into how modern laboratory information system (LIS) software can ensure compliance with any future regulatory requirements.

What Happened with the FDA’s LDT Final Rule

In May 2024, the FDA published a final rule intended to bring laboratory-developed tests (LDTs) under the same regulatory framework as other in vitro diagnostics (IVDs), meaning clinical labs and pathology groups would have to comply with medical device requirements, including premarket review.

However, on March 31, 2025, a U.S. federal district court (Eastern District of Texas) vacated that final rule, judging that the FDA had exceeded its statutory authority by attempting to regulate LDTs as medical devices under the Federal Food, Drug, and Cosmetic Act (FDCA). The court held that LDTs are services regulated under the Clinical Laboratory Improvement Amendments (CLIA), not devices subject to FDA device authority.

The FDA declined to appeal the court decision and, in September 2025, issued a new final rule that reverted the regulatory language to the pre-2024 definition of in vitro diagnostic products. This effectively rescinded the 2024 LDT rule, restoring the status quo where the FDA continues to exercise enforcement discretion rather than enforce mandatory device-style regulation for most LDTs.

What Remains Uncertain

Despite the reversal, the long-term future of LDT oversight remains unsettled. Questions remain about potential future legislation or rulemaking, alternative authorization pathways, and FDA’s approach to previously submitted applications. In the meantime, laboratories must continue to maintain rigorous validation, quality control, documentation, and inspection readiness under existing requirements. 

A Quick Look Back: Dark Daily, “Three Possible Scenarios for LDT Regulation after Historic Court Decision Vacates FDA Final Rule,” April 2, 2025.

Why Modern Laboratory Information Systems Are Essential for Labs Facing Heightened Oversight and Compliance Pressure

Even before the FDA first announced and later rescinded its final rule on LDTs, clinical laboratories and pathology practices faced extreme pressure to maintain high-quality standards while ensuring operational compliance. To protect themselves and remain relevant, medical labs must modernize and deploy comprehensive LIS (laboratory information system) software to address current and future challenges.

To help laboratory leaders navigate these challenges and safeguard their operations, we've provided a detailed overview of the key laboratory information system functions and components required to support modern laboratory operations and efficient lab workflows.

Discover More: The Best Laboratory Information Systems - LIS Software Solutions for Clinical and Pathology Labs

Compliance Management

One of the most significant challenges for laboratories today is navigating the maze of regulatory requirements. An ideal LIS lab software solution must have robust compliance management features to keep labs informed and aligned with evolving standards.

• Regulatory Tracking: By integrating real-time feeds from relevant regulatory bodies, laboratories can stay up to date on changes, deadlines, and new guidelines. Users can configure automated alerts and notifications to inform personnel of upcoming compliance tasks.
• Document Control: Secure management of standard operating procedures (SOPs), validation records, and quality control documentation is essential. The LIS software should offer version control, audit trails, and access logs to ensure document integrity.
• Audit Trail: This functionality provides comprehensive and transparent tracking of all user activities within the lab information system. This feature ensures complete traceability by recording every real-time action, including data modifications, user access, and system changes.

Discover More: A Detailed Look at How Modern Laboratory Information Systems Fully Support Quality Control

Data Management and Integration

Laboratory data management must be centralized and interoperable to maintain integrity and accessibility across various laboratory software systems.

• Centralized Data Repository: A unified LIS system database consolidates test results, patient records, and sample tracking, enabling easy access and efficient management of laboratory data.
• Integration with Existing Systems: Compatibility with hospital and laboratory software systems (such as electronic health records, instrument interoperability, and laboratory billing/lab revenue cycle management software) enables smooth data transfer and minimizes errors associated with manual data entry.
• Cloud-Based Solutions: Cloud storage provides scalability and ensures data availability. Robust encryption protocols and backup systems are critical for data security.

Industry Insights: Examining the Pros and Cons of Cloud-Based LIS System Solutions

Sample Management

Accurate, timely sample tracking is crucial for maintaining reliability and patient trust.

• Barcoding and Tracking: Automated sample identification using barcodes ensures each sample is accurately tracked throughout its lifecycle, minimizing errors.
• Workflow Automation: Alerts and notifications keep laboratory staff informed of specimen status and testing progress. This reduces delays and improves workflow transparency.

Test Validation and Quality Control

Quality and reliability are key components of laboratory testing.

• Validation Tools: LIS system tools should guide laboratories through test validation processes that comply with regulatory standards.
• Quality Control Modules: Advanced QC modules can compare test results against control samples to identify anomalies and ensure consistency. 

Reporting and Analytics

Comprehensive reporting and data analysis drive better decision-making and streamline compliance.

• Customizable Reporting: Laboratories should be able to generate reports that meet internal needs, client demands, and regulatory requirements, including audit-ready formats for FDA inspections.
• Advanced Analytics: Data analytics help laboratories identify trends, anticipate equipment issues, optimize resource utilization, and generate actionable insights that drive greater efficiency.

Discover More: How LigoLab's Pathology Lab Software Supports Lab Report Customization and Client Preferences

User Access and Security

Secure and customizable access is vital for protecting sensitive data.

• Role-Based Access Control (RBAC): Role-specific permissions ensure data is accessible only to authorized personnel.
• Data Encryption and Security: Strong at-rest and in-transit encryption ensures that sensitive patient data remains protected from breaches.

Discover More: LigoLab’s Enhanced Cybersecurity Solutions Give Customers Added Protection and Peace of Mind

Support and Scalability

As laboratories scale, their laboratory information system software solutions should scale seamlessly.

• Technical Support: Highly responsive customer support provides timely training, troubleshooting assistance, and ongoing system updates.
• Scalability: The lab information system must handle increased test volumes without significant re-investment, adjusting to growing needs.

User Interface and Usability

An intuitive, user-friendly laboratory information system design is essential for user adoption and reducing errors.

• Intuitive Interface: A user-friendly interface with easy navigation reduces training time and error rates.
• Mobile Compatibility: Mobile compatibility provides flexible access to the LIS system, enhancing productivity.

To effectively support medical laboratories, leading laboratory information system companies must continue to push the limits of comprehensive, adaptable, and robust LIS pathology and clinical laboratory management solutions.

Discover More: 6 Ways to Improve Revenue and Lower Costs to Offset Reimbursement Cuts

LigoLab’s All-in-One Medical LIS & Lab RCM Informatics Platform

The all-in-one LigoLab Informatics Platform is a comprehensive laboratory information system and laboratory revenue cycle management solution designed to help pathology groups and clinical labs digitally transform into modern, efficient organizations that are more productive and profitable.

LigoLab's enterprise-grade LIS software platform features all of the functionality listed above, plus integrated modules for anatomic pathology, clinical laboratory, molecular diagnostics, laboratory billing, and direct-to-consumer lab testing (TestDirectly) workflows.

All modules and features are embedded within a single lab software database and infrastructure, eliminating data silos and efficiently managing all departments and operations with maximum interoperability.

Discover More: Navigating the Future of Pathology: The LigoLab Advantage

Ready to Transform Your Laboratory?

See how LigoLab's comprehensive, flexible medical LIS and lab revenue cycle management platform can modernize your operations, reduce complexity, and support long-term growth. Contact our team today to start the conversation. 

Act Now: Speak With a Product Specialist

Frequently Asked Questions About the FDA's LDT Final Rule

What did the FDA's original 2024 LDT final rule propose?

Published in May 2024, the rule aimed to bring laboratory-developed tests under the same regulatory framework as other in vitro diagnostics, requiring clinical labs and pathology groups to comply with medical device requirements, including premarket review.

Why was the FDA's LDT final rule vacated?

On March 31, 2025, a U.S. federal district court in the Eastern District of Texas ruled that the FDA exceeded its statutory authority, finding that LDTs are services regulated under CLIA, not medical devices subject to FDA device authority.

What happened after the court ruling?

The FDA declined to appeal and, in September 2025, issued a new final rule reverting to the pre-2024 definition of in vitro diagnostic products, effectively rescinding the 2024 LDT rule.

Who regulates LDTs now?

LDTs are primarily regulated under CLIA, administered by CMS, rather than through FDA device premarket requirements, restoring the FDA's prior approach of enforcement discretion.

What LIS capabilities help labs stay ready for regulatory change?

Key capabilities include compliance management with regulatory tracking and audit trails, centralized, interoperable data management, barcoded sample tracking, test validation and QC tools, customizable audit-ready reporting, role-based access control and encryption, and scalable, mobile-friendly system design.

How does LigoLab's platform support labs navigating LDT and regulatory uncertainty?

LigoLab's all-in-one LIS & RCM platform includes the compliance, data management, and reporting functionality labs need, combined with integrated modules for anatomic pathology, clinical laboratory, molecular diagnostics, and lab billing, all on a single infrastructure that eliminates data silos.